KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Gross Margin (2016 - 2025)

Pfizer (PFE) has disclosed Gross Margin for 17 consecutive years, with 83.48% as the latest value for Q4 2025.

  • On a quarterly basis, Gross Margin fell 3229.0% to 83.48% in Q4 2025 year-over-year; TTM through Dec 2025 was 74.33%, a 11454.0% decrease, with the full-year FY2025 number at 74.33%, up 18714.0% from a year prior.
  • Gross Margin was 83.48% for Q4 2025 at Pfizer, up from 81.51% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 115.77% in Q4 2024 to a low of 1090.72% in Q3 2024.
  • A 5-year average of 29.0% and a median of 62.04% in 2021 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: crashed -112202bps in 2024, then skyrocketed 100922bps in 2025.
  • Pfizer's Gross Margin stood at 58.78% in 2021, then increased by 25bps to 73.22% in 2022, then crashed by -264bps to 120.21% in 2023, then soared by 196bps to 115.77% in 2024, then decreased by -28bps to 83.48% in 2025.
  • Per Business Quant, the three most recent readings for PFE's Gross Margin are 83.48% (Q4 2025), 81.51% (Q3 2025), and 74.21% (Q2 2025).